Published on 5 Apr 2024 on Benzinga
Ocugen, Inc. OCGN shares are trading higher Friday after the company announced it has received approval to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of its Phase 1/2 study.
The Details: